Skip to main content
Cloudy icon
48º

‘Glimmer of hope’ seen for Remdesivir coronavirus treatment trials

FILE - In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. On Wednesday, April 29, 2020, the company says its experimental antiviral drug has proved effective against the new coronavirus in a major U.S. government study that put it to a strict test. (Gilead Sciences via AP) (Uncredited, Gilead Sciences)

The Emory University medical school doctor leading the Remdesivir drug trials says the drug provides a “glimmer of hope” for coronavirus treatment.

Aneesh Mehta said Thursday on ABC’s “Good Morning America” that “we are looking to find a medication that helps patients get better more rapidly, get them home to their families and make more room for other patients for us to take care of.”

Recommended Videos



He adds: “I think now we have the first glimmer of hope of something that can do that.”

Mehta cautions that the Remdesivir data is “very preliminary.” He says most antivirals tend to work better earlier in the course of disease.

He adds that his team is working with the National Institutes of Health to adapt the clinical trial to look at other medications in combination with Remdesivir.

Read more: Dr. Fauci expresses optimism for treating COVID-19 with antiviral drug remdesivir


Recommended Videos